Colony Group LLC trimmed its position in shares of Medpace Holdings Inc (NASDAQ:MEDP) by 0.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 31,354 shares of the company’s stock after selling 226 shares during the period. Colony Group LLC owned 0.09% of Medpace worth $2,636,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MEDP. MERIAN GLOBAL INVESTORS UK Ltd raised its position in Medpace by 382.8% during the fourth quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 250,882 shares of the company’s stock valued at $21,089,000 after buying an additional 198,922 shares during the period. Man Group plc grew its stake in Medpace by 100.7% during the 4th quarter. Man Group plc now owns 367,238 shares of the company’s stock valued at $30,870,000 after acquiring an additional 184,221 shares in the last quarter. Renaissance Technologies LLC grew its stake in Medpace by 23.7% during the 4th quarter. Renaissance Technologies LLC now owns 586,088 shares of the company’s stock valued at $49,267,000 after acquiring an additional 112,100 shares in the last quarter. Voloridge Investment Management LLC acquired a new position in shares of Medpace in the 3rd quarter valued at about $5,921,000. Finally, Squarepoint Ops LLC increased its holdings in shares of Medpace by 181.1% in the 3rd quarter. Squarepoint Ops LLC now owns 105,483 shares of the company’s stock valued at $8,865,000 after purchasing an additional 67,964 shares during the period. Hedge funds and other institutional investors own 79.63% of the company’s stock.

Shares of NASDAQ MEDP opened at $67.97 on Thursday. The stock has a market cap of $2.50 billion, a price-to-earnings ratio of 25.65 and a beta of 1.23. The business has a 50 day simple moving average of $89.21 and a 200 day simple moving average of $82.90. Medpace Holdings Inc has a 52 week low of $52.84 and a 52 week high of $109.09. The company has a debt-to-equity ratio of 0.06, a quick ratio of 0.92 and a current ratio of 0.92.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.10. The firm had revenue of $229.89 million for the quarter, compared to analyst estimates of $221.73 million. Medpace had a net margin of 11.67% and a return on equity of 16.80%. The company’s revenue for the quarter was up 19.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.76 earnings per share. On average, analysts predict that Medpace Holdings Inc will post 3.23 EPS for the current year.

A number of research analysts recently commented on MEDP shares. SunTrust Banks downgraded shares of Medpace from a “hold” rating to a “sell” rating and lowered their price objective for the company from $100.00 to $46.00 in a research report on Tuesday, March 17th. Zacks Investment Research downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Tuesday. CSFB lifted their target price on shares of Medpace from $91.00 to $99.00 and gave the company an “outperform” rating in a research note on Tuesday, February 25th. Credit Suisse Group boosted their price target on shares of Medpace from $91.00 to $99.00 and gave the company an “outperform” rating in a report on Tuesday, February 25th. Finally, BidaskClub cut shares of Medpace from a “buy” rating to a “hold” rating in a report on Friday, March 13th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $82.33.

Medpace Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Read More: How to calculate the intrinsic value of a stock

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.